• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article (55070837)   Find a Category (126)   Find a Journal (6147)   Find a Scholar (3941)   Find an Academic Assistant (17)
Find an Article PDF (4594742)   Today's Articles (1316)   Subscriber (49325)
Citation(s) in RCA

Indexed Articles
Ranked By
Results Analysis
  •   
  •   
  •   
  •   
Results Analysis
Year Published
Show more   Refine
For: Lipton A, Fizazi K, Stopeck A, Henry D, Brown J, Saad F, Yardley D, Maroto P, Ke C, Jun S. 3061 POSTER Prevention of Skeletal-Related Events With Denosumab or Zoledronic Acid – Combined Analysis From 3 Registrational Trials. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71134-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Number Cited by Other Article(s)
1
Cicci JD, Buie L, Bates J, van Deventer H. Denosumab for the Management of Hypercalcemia of Malignancy in Patients With Multiple Myeloma and Renal Dysfunction. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 2014;14:e207-11. [DOI: 10.1016/j.clml.2014.07.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Revised: 07/01/2014] [Accepted: 07/08/2014] [Indexed: 10/25/2022]
2
Lipton A, Balakumaran A. Denosumab for the treatment of cancer therapy-induced bone loss and prevention of skeletal-related events in patients with solid tumors. Expert Rev Clin Pharmacol 2014;5:359-71. [DOI: 10.1586/ecp.12.35] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA